Nontuberculous mycobacteria (NTM) are difficult-to-treat pathogens associated with serious pulmonary chronic infections in cystic fibrosis (CF) patients. Among NTM, the particularly frequent Mycobacterium avium complex quickly develops multidrug resistance, due to the overexpression of efflux pumps (EPs) that promotes an increased extrusion of antimycobacterial drugs from the Mycobacterium cell. Therefore, the development of potent EP inhibitors (EPIs) is a promising strategy to fight M. avium infections and restore the sensitivity to ineffective drugs. Researchers have already identified a new class of M. avium EPI compounds based on the 3-phenylquinolone nucleus. In this project, carrying out a multidisciplinary approach entailing drug design, chemical synthesis, and biological evaluation, they aim to identify a new class of drugs (EPIs) against M. avium, derived from the 3- phenylquinolone and to be tested in future pre-clinical studies in animal models.